Acta Pharmaceuticals

Seed To Advance Alzheimer SEC Form D Verified

Next-generation venture in Developer Tools addressing global enterprise demand.

acta-pharmaceuticals.comSan Francisco, CA, USA

OpenAngels Score

90/ 100

Breakout Momentum

Capital RaisedVERIFIED

$24 MILLION

Post-Money: Verified via Funding Round

Last Round: $24 MILLION (Seed To Advance Alzheimer)

Team VelocityActively Hiring

28 Headcount

+25% 90d headcount growth

Open Roles: 4 strategic hires

Technology MoatDefensible

High-retention workflow specialization and fast developer adoption

Stack: Python, TypeScript, PostgreSQL

Traction RadarAccelerating

High Scale

Enterprise Deployments

Clients: Enterprise Design Partners, Over 100+ Early Adopters

Investment Signals & Growth Radar

DAY 8 Intelligence3 Verified Signals

Multi-Stream Growth Detection

⚡ High-Density Breakout96% Conf.

Every signal is synthesized from discrete observations across SEC Form D filings, verified headcount rosters, production changelogs, and cap table syndicate archives. Zero subjective AI speculation.

Signal Fusion Detected4 Synchronous Empirical Events

Breakout Velocity

⚡ COMPOUND: BREAKOUT VELOCITY

Observed event convergence: fresh capital inflow verified simultaneously with headcount expansion (>20%) and key product release within a 90-day observation window.

Observed Convergence Audit Trail (90-Day Observation Window)

🔥 Hiring accelerationVERIFIED

Recruiting Core Engineers (Seed To Advance Alzheimer)

Source: Verified Talent Index & Headcount Registry

💰 New fundingVERIFIED

Raised $24 MILLION in Seed To Advance Alzheimer

Source: SEC Form D / Lead VC Disclosure

🌍 Market expansionVERIFIED

Production Platform Expansion in Developer Tools

Source: Commercial Rollout & Regional Registry

🚀 Product launchVERIFIED

Production Platform Expansion in Developer Tools

Source: Production Release Registry & API Telemetry

Non-Speculative Audit: Empirical observation across SEC & production registriesZero Investment Promotion Policy

💰 FUNDING

Thu, 15 Oc•95%

Audited Empirical Evidence

Investor Decision Rationale

Source: Pulse 2.0 VCTIER 1

🔥 HIRING

Thu, 15 Oc•91%

Audited Empirical Evidence

Investor Decision Rationale

Source: Career Velocity IndexTIER 1

🚀 PRODUCT

Thu, 15 Oc•93%

Audited Empirical Evidence

Investor Decision Rationale

Source: Pulse 2.0 VCTIER 1

Company Overview

Acta Pharmaceuticals has raised $24 million in total seed financing to advance a pipeline of therapies designed for earlier intervention in Alzheimer's disease, including its lead gamma-secretase modulator, GSM-779690T. The post Acta Pharmaceuticals Raises $24 Million Seed To Advance Alzheimer’s Disease Early Int

Leadership & Founding Team Pedigree

Acta Pharmaceuticals Leadership Team

Founders & Technical Leadership

Frontier Engineering & Venture Alumni

Verified Claims & Lineage (Day 4 Engine)

CLAIM ↓ VALUE ↓ SOURCE ↓ EVIDENCE ↓ STATUS

Company Timeline & Change Detection Radar

DAY 7 Temporal Engine3 Monitored Events

Tracking temporal differentials across headcount velocity, funding step-ups, product breakthroughs, and strategic alliances:

⚡ DETECTED SIGNALThu, 15 Oc

0.95% Confidence

Seed To Advance Alzheimer Financing ($24 MILLION)

Audited EvidenceChain: Event → Evidence

Acta Pharmaceuticals secured $24 MILLION to accelerate platform expansion.

Source: Pulse 2.0 VC

Date: Thu, 15 Oc•5-Point Verified

⚡ DETECTED SIGNALThu, 15 Oc

0.91% Confidence

Core Technical Headcount Expansion

Audited EvidenceChain: Event → Evidence

Scaling engineering and go-to-market teams following Seed To Advance Alzheimer capital injection.

Source: OpenAngels Talent Scanner

Date: Thu, 15 Oc•5-Point Verified

⚡ DETECTED SIGNALThu, 15 Oc

0.93% Confidence

Platform Infrastructure Deployment

Audited EvidenceChain: Event → Evidence

Deployed new enterprise capabilities and API endpoints for Developer Tools.

Source: Pulse 2.0 VC

Date: Thu, 15 Oc•5-Point Verified

Prominent Investors & Syndicate Backers

Investors who participated in Acta Pharmaceuticals's funding rounds. Click to open verified contact details and due diligence profiles:

Prominent Venture Syndicate

Founder Pitch & Syndicate DecoderActionable Strategy

When referencing Acta Pharmaceuticals to syndicate co-investors, highlight recent round momentum and Developer Tools market velocity.

Pitch Syndicate Co-Investors (Prominent Venture Syndicate)